In Focus: iPSCs and MSCs
Induced pluripotent stem cells (iPSCS) and mesenchymal stem cells (MSCs) have transformative potential in regenerative medicine and cell therapy, with iPSCs offering versatility through their ability to differentiate into virtually any cell type and MSCs providing immunomodulatory and anti-inflammatory properties.
In this In Focus feature, Sartorius (Göttingen, Germany) has partnered with us to share their expertise as we explore the similarities and differences between these two key stem cell types and examine critical hurdles that can arise during their development and manufacturing.
Infographic
iPSCs and MSCs: considerations for development and manufacturing
This infographic explores the key challenges in developing and manufacturing iPSCs and MSCs for cell therapy and regenerative medicine. From biological hurdles — such as source variability, genetic stability and cellular senescence, that impact fundamental cellular properties — to process control obstacles like standardization and scalability when transitioning from laboratory research to clinical manufacturing, and finally, regulatory requirements demanding rigorous testing and documentation to satisfy safety and efficacy standards.
Interview
Navigating the technical landscape of stem cell therapy production
Alyssa Clearwood, Platform Development Specialist at Sartorius, gives her insight into how cell therapy developers and manufacturers can navigate the technical and regulatory challenges that arise when working with iPSCs and MSCs. Alyssa explores how automation and bioreactor technologies enhance manufacturing efficiency, strategies for optimizing differentiation protocols, and best practices for developing robust processes across variable cell sources.
Resources
Solutions for the culturing, maintaining and characterization of induced pluripotent stem cells
This article was created in association with Sartorius.
